Amgen (AMG 337) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
1
Amgen (AMG 337) General Information
Description
A mid-stage anticancer MET inhibitor drug. The compound is a phase 2 small molecule inhibitor of the cell surface enzyme which stimulates cancer cell scattering, invasion and protection from apoptosis. It is being developed to treat gastric and esophageal cancers.
Contact Information
Corporate Office
- One Amgen Center Drive
- Thousand Oaks, CA 91320
- United States
Corporate Office
- One Amgen Center Drive
- Thousand Oaks, CA 91320
- United States
Amgen (AMG 337) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Amgen (AMG 337) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Amgen (AMG 337) FAQs
-
Where is Amgen (AMG 337) headquartered?
Amgen (AMG 337) is headquartered in Thousand Oaks, CA.
-
What industry is Amgen (AMG 337) in?
Amgen (AMG 337)’s primary industry is Buildings and Property.
-
Is Amgen (AMG 337) a private or public company?
Amgen (AMG 337) is a Private company.
-
What is Amgen (AMG 337)’s current revenue?
The current revenue for Amgen (AMG 337) is
. -
Who are Amgen (AMG 337)’s investors?
Amgen has invested in Amgen (AMG 337).
-
When was Amgen (AMG 337) acquired?
Amgen (AMG 337) was acquired on 14-Sep-2015.
-
Who acquired Amgen (AMG 337)?
Amgen (AMG 337) was acquired by NantPharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »